# CagriSema vs Tirzepatide: How They Differ | PepVault

Source: https://pepvault.app/peptides/compare/cagrisema-vs-tirzepatide

Last updated: 2026-10-06

Use: © PepVault. Read and cite with a link. Copying, bulk scraping, rewriting or republishing is not permitted (https://pepvault.app/terms#content).

[Library](https://pepvault.app/peptides) [Comparisons](https://pepvault.app/peptides/compare) CagriSema vs Tirzepatide

Compared side by side

# CagriSema vs tirzepatide: how they differ

Reviewed October 2026 [How we check the library](https://pepvault.app/about#library) [Published by PepVault](https://pepvault.app/guides/how-we-research)

## The short answer

Both are weekly shots that pair GLP-1 with a second hormone: CagriSema combines semaglutide (GLP-1) with cagrilintide, an amylin analogue, and tirzepatide is one molecule that activates the GLP-1 and GIP receptors. Tirzepatide is FDA-approved, as Mounjaro and Zepbound; CagriSema isn’t approved yet, and Novo Nordisk filed it with the FDA in December 2025. In their own trials, CagriSema averaged about 20% weight loss at 68 weeks, and tirzepatide’s 15 mg up to 22.5% at 72 weeks (SURMOUNT-1).

## Side by side

| Compared | [CagriSema](https://pepvault.app/peptides/cagrisema) | [Tirzepatide](https://pepvault.app/peptides/tirzepatide) |
| --- | --- | --- |
| Category | Metabolic & GLP-1 | Metabolic & GLP-1 |
| Also known as | Cagrilintide/semaglutide, Cagrilintide-semaglutide, Cagri-Sema, Cagri + Sema | Mounjaro, Zepbound, LY3298176 |
| What it is | Two weekly drugs in one regimen: cagrilintide, a long-acting version of the fullness hormone amylin, and semaglutide, the GLP-1 drug in Wegovy and Ozempic. | The first dual GIP/GLP-1 receptor agonist: it activates two gut-hormone pathways at once, and in a head-to-head trial it produced more weight loss than semaglutide (20.2% vs 13.7% at 72 weeks). |
| How it works | Weekly combination of two long-acting hormone analogues: cagrilintide, an amylin analogue that acts on amylin and calcitonin receptors, and semaglutide, a GLP-1 receptor agonist. Amylin and GLP-1 curb appetite through partly different brain pathways, so their effects add up: in REDEFINE 1 the pair lost more weight than either drug alone. Doses are written per component (2.4 mg/2.4 mg is 2.4 mg of each). Not approved: Novo Nordisk filed it with the FDA in December 2025, and a decision is expected in the fourth quarter of 2026. | Dual GIP/GLP-1 receptor agonist. Significantly reduces body weight through appetite suppression, slowed gastric emptying, and improved insulin sensitivity. Approved for T2DM and obesity management. |
| Commonly reported | Strong appetite suppression and early fullness, with nausea, vomiting or constipation through the dose steps. In its main trial people lost about 20% of body weight on average at 68 weeks, more than on semaglutide alone; it is not approved yet. | Very strong appetite suppression and meals ending early, with nausea or tiredness for a day or two after the injection, mostly after dose increases. FDA-approved for diabetes (Mounjaro) and for weight management and sleep apnea (Zepbound). |
| Studied range | Research range: 0.25–2.4 mg, starting dose 0.25 mg. Studied in research — not a recommendation. | FDA label: 2.5–15 mg, starting dose 2.5 mg. |
| How often | Weekly | Weekly |
| Half-life | ~1 week for each component (measured in people: cagrilintide 159–195 hours and semaglutide 145–165 hours in a phase 1b trial) | ~5 days (FDA label) |
| Route | SubQ injection | SubQ injection |
| Typical run | Studied as an ongoing weekly treatment: 68 to 84 weeks in phase 3. Not approved yet; Novo Nordisk filed for US approval in December 2025. | FDA-approved for ongoing use. Titrate slowly upward. Community maintains on minimum effective dose. |
| Evidence | Established: clinical trials or FDA-approved use exists | Established: clinical trials or FDA-approved use exists |
| Common side effects | Nausea, vomiting, diarrhea, constipation, abdominal pain | Nausea, diarrhea, vomiting, constipation, abdominal pain, decreased appetite, fatigue |

Typical run: Community practice — opinions vary. Not a clinical recommendation.

<!--promo-->

Model. Individual results vary.

PepVault for iPhone

## Taking CagriSema or tirzepatide? Log it in PepVault

Each dose, each vial and your step-ups in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=compound-vs-card-flow&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## Week by week

Each entry’s cards by day window, as the compound pages show them. Day 1 is the day you start it.

### CagriSema

- Day 1–28 · 0.25 mg The 0.25 mg start
- Day 29–364 · 0.5 mg 0.5 mg of each
- Day 57–364 · 1 mg 1 mg of each, halfway up
- Day 85–364 · 1.7 mg 1.7 mg of each, one step from the top
- Day 113+ · 2.4 mg 2.4 mg/2.4 mg, the maintenance dose

[Every card for CagriSema, with its sources](https://pepvault.app/peptides/cagrisema#weeks)

### Tirzepatide

- Day 1–28 · 2.5 mg Getting your gut acclimated
- Day 29–56 · 5 mg First therapeutic dose — weight drops
- Day 57–112 · 7.5 mg Dual agonism in full effect
- Day 113–168 · 12.5 mg Max titration reached
- Day 169–504 Weeks 24 to 72: where most people plateau
- Day 365+ A maintenance medication, not a course

[Every card for tirzepatide, with its sources](https://pepvault.app/peptides/tirzepatide#weeks)

## With this comparison

### CagriSema

- [CagriSema: the full reference](https://pepvault.app/peptides/cagrisema)
- [CagriSema dose guide](https://pepvault.app/lab/dosage/cagrisema)

### Tirzepatide

- [Tirzepatide: the full reference](https://pepvault.app/peptides/tirzepatide)
- [Tirzepatide dose guide](https://pepvault.app/lab/dosage/tirzepatide)

### Mixing charts

- [Tirzepatide 5 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-5mg)
- [Tirzepatide 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-10mg)
- [Tirzepatide 15 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-15mg)
- [Tirzepatide 30 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-30mg)
- [Tirzepatide 60 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-60mg)

### Studies

- [CagriSema: 18.4% weight loss vs 11.9% on semaglutide in REDEFINE 5](https://pepvault.app/research/cagrisema-redefine-5-2026)
- [The study on the research page](https://pepvault.app/research#cagrisema)
- [Tirzepatide plus apitegromab: 1.9 kg less lean mass loss in EMBRAZE](https://pepvault.app/research/tirzepatide-embraze-2026)
- [Dulaglutide: switching to tirzepatide beat dose escalation on HbA1c](https://pepvault.app/research/dulaglutide-surpass-switch-2025)
- [Tirzepatide: up to 19.7% weight loss at 176 weeks in SURMOUNT-1](https://pepvault.app/research/tirzepatide-surmount-1-2025-39536238)
- [All 15 studies](https://pepvault.app/research#tirzepatide)

### Compared with

- [CagriSema vs Semaglutide](https://pepvault.app/peptides/compare/cagrisema-vs-semaglutide)
- [Retatrutide vs Tirzepatide](https://pepvault.app/peptides/compare/retatrutide-vs-tirzepatide)
- [Semaglutide vs Tirzepatide](https://pepvault.app/peptides/compare/semaglutide-vs-tirzepatide)
- [Mazdutide vs Tirzepatide](https://pepvault.app/peptides/compare/mazdutide-vs-tirzepatide)
- [Tirzepatide vs Liraglutide](https://pepvault.app/peptides/compare/tirzepatide-vs-liraglutide)
- [Tirzepatide vs Dulaglutide](https://pepvault.app/peptides/compare/tirzepatide-vs-dulaglutide)

### Tools

- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [How long will my vial last?](https://pepvault.app/tools/how-long-will-my-vial-last)
- [Is my mixed vial still good?](https://pepvault.app/tools/reconstituted-peptide-expiry)
- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)
- [GLP-1 titration planner](https://pepvault.app/tools/glp1-titration-calculator)
- [GLP-1 weight loss by week](https://pepvault.app/tools/glp1-weight-loss-by-week)

### Terms on this page

- [Receptor agonist](https://pepvault.app/glossary/receptor-agonist)
- [Subcutaneous (SubQ)](https://pepvault.app/glossary/subcutaneous)
- [Half-life](https://pepvault.app/glossary/half-life)
- [GLP-1](https://pepvault.app/glossary/glp-1)
- [GIP](https://pepvault.app/glossary/gip)

## Questions people ask

### How long do CagriSema and tirzepatide last?

The half-life of CagriSema is ~1 week for each component (measured in people: cagrilintide 159–195 hours and semaglutide 145–165 hours in a phase 1b trial). The half-life of tirzepatide is ~5 days (FDA label).

### How often are CagriSema and tirzepatide taken?

CagriSema: weekly. Route: SubQ injection. Tirzepatide: weekly. Route: SubQ injection.

### How are CagriSema and tirzepatide dosed in research?

The research range for CagriSema is 0.25–2.4 mg, with a 0.25 mg starting dose. Studied in research — not a recommendation. The FDA label range for tirzepatide is 2.5–15 mg, with a 2.5 mg starting dose.

### What are the common side effects of CagriSema and tirzepatide?

For CagriSema, the library lists: nausea, vomiting, diarrhea, constipation, abdominal pain. For tirzepatide: nausea, diarrhea, vomiting, constipation, abdominal pain, decreased appetite, fatigue.

## Each one in full

- [CagriSema: dosage, half-life & reference guide](https://pepvault.app/peptides/cagrisema)
- [Tirzepatide: dosage, half-life & reference guide](https://pepvault.app/peptides/tirzepatide)
- [CagriSema dose guide](https://pepvault.app/lab/dosage/cagrisema)
- [Tirzepatide dose guide](https://pepvault.app/lab/dosage/tirzepatide)

<!--promo-->

[Track it in the app](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=compound-vs-card-next&mt=8)

<!--/promo-->

<!--promo-->

PepVault for iPhone

## Taking CagriSema or tirzepatide? Log it in PepVault

Each dose, each vial and your step-ups in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=compound-vs-card-end&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

<!--promo-->

Model. Individual results vary.

PepVault for iPhone

## Taking CagriSema or tirzepatide? Log it in PepVault

Each dose, each vial and your step-ups in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=compound-vs-card-rail&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## With this comparison

### CagriSema

- [CagriSema: the full reference](https://pepvault.app/peptides/cagrisema)
- [CagriSema dose guide](https://pepvault.app/lab/dosage/cagrisema)

### Tirzepatide

- [Tirzepatide: the full reference](https://pepvault.app/peptides/tirzepatide)
- [Tirzepatide dose guide](https://pepvault.app/lab/dosage/tirzepatide)

### Mixing charts

- [Tirzepatide 5 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-5mg)
- [Tirzepatide 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-10mg)
- [Tirzepatide 15 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-15mg)
- [Tirzepatide 30 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-30mg)
- [Tirzepatide 60 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-60mg)

### Studies

- [CagriSema: 18.4% weight loss vs 11.9% on semaglutide in REDEFINE 5](https://pepvault.app/research/cagrisema-redefine-5-2026)
- [The study on the research page](https://pepvault.app/research#cagrisema)
- [Tirzepatide plus apitegromab: 1.9 kg less lean mass loss in EMBRAZE](https://pepvault.app/research/tirzepatide-embraze-2026)
- [Dulaglutide: switching to tirzepatide beat dose escalation on HbA1c](https://pepvault.app/research/dulaglutide-surpass-switch-2025)
- [Tirzepatide: up to 19.7% weight loss at 176 weeks in SURMOUNT-1](https://pepvault.app/research/tirzepatide-surmount-1-2025-39536238)
- [All 15 studies](https://pepvault.app/research#tirzepatide)

### Compared with

- [CagriSema vs Semaglutide](https://pepvault.app/peptides/compare/cagrisema-vs-semaglutide)
- [Retatrutide vs Tirzepatide](https://pepvault.app/peptides/compare/retatrutide-vs-tirzepatide)
- [Semaglutide vs Tirzepatide](https://pepvault.app/peptides/compare/semaglutide-vs-tirzepatide)
- [Mazdutide vs Tirzepatide](https://pepvault.app/peptides/compare/mazdutide-vs-tirzepatide)
- [Tirzepatide vs Liraglutide](https://pepvault.app/peptides/compare/tirzepatide-vs-liraglutide)
- [Tirzepatide vs Dulaglutide](https://pepvault.app/peptides/compare/tirzepatide-vs-dulaglutide)

### Tools

- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [How long will my vial last?](https://pepvault.app/tools/how-long-will-my-vial-last)
- [Is my mixed vial still good?](https://pepvault.app/tools/reconstituted-peptide-expiry)
- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)
- [GLP-1 titration planner](https://pepvault.app/tools/glp1-titration-calculator)
- [GLP-1 weight loss by week](https://pepvault.app/tools/glp1-weight-loss-by-week)

### Terms on this page

- [Receptor agonist](https://pepvault.app/glossary/receptor-agonist)
- [Subcutaneous (SubQ)](https://pepvault.app/glossary/subcutaneous)
- [Half-life](https://pepvault.app/glossary/half-life)
- [GLP-1](https://pepvault.app/glossary/glp-1)
- [GIP](https://pepvault.app/glossary/gip)

<!--promo-->

PepVault for iPhone

## Taking CagriSema or tirzepatide? Log it in PepVault

Each dose, each vial and your step-ups in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=compound-vs-card-sticky&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

## More comparisons

- [All peptide comparisons](https://pepvault.app/peptides/compare)
- [Retatrutide vs Tirzepatide](https://pepvault.app/peptides/compare/retatrutide-vs-tirzepatide)
- [Semaglutide vs Tirzepatide](https://pepvault.app/peptides/compare/semaglutide-vs-tirzepatide)
- [Mazdutide vs Tirzepatide](https://pepvault.app/peptides/compare/mazdutide-vs-tirzepatide)
- [Tirzepatide vs Liraglutide](https://pepvault.app/peptides/compare/tirzepatide-vs-liraglutide)
- [Tirzepatide vs Dulaglutide](https://pepvault.app/peptides/compare/tirzepatide-vs-dulaglutide)
- [Orforglipron vs Tirzepatide](https://pepvault.app/peptides/compare/orforglipron-vs-tirzepatide)

## The library

- [The peptide reference library](https://pepvault.app/peptides)
- [Metabolic & GLP-1 peptides](https://pepvault.app/peptides#metabolic)

## Free tools

- [The Dose Guide](https://pepvault.app/lab/dosage)
- [Half-life & active level](https://pepvault.app/tools/peptide-half-life-calculator)
- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [GLP-1 titration planner](https://pepvault.app/tools/glp1-titration-calculator)

PepVault is a research and tracking resource, not medical advice. Ranges are what studies used, never a dose for you. Brand names are trademarks of their owners; PepVault is independent of them.

PepVault is a private research and tracking tool, not medical advice. The information here is reference material from published literature and community use — always verify it and discuss any protocol with a qualified clinician before changing it. Ozempic, Wegovy, Rybelsus, Mounjaro, Zepbound, Saxenda, Victoza and Trulicity are trademarks of their respective owners; PepVault is independent and not affiliated with or endorsed by any manufacturer.

© 2026 PepVault. Our text, data and tools may not be copied, scraped or republished without [permission](https://pepvault.app/terms#content).
